查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1573007

血癌药物市场：按药物类型、疾病类型、治疗类型、最终用户、剂型划分 - 全球预测 2025-2030

Blood Cancer Drugs Market by Drug Type (Chemotherapy, Immunotherapy, Targeted Therapy), Disease Type (Leukemia, Lymphoma, Multiple Myeloma), Treatment Type, End-User, Drug Formulation - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年血癌药物市场价值为427.8亿美元，预计到2024年将达到459.8亿美元，复合年增长率为9.90%，到2030年将达到828.7亿美元。

血癌药物的范围集中在用于治疗各种类型血癌的药物，包括白血病、淋巴瘤和骨髓瘤。这些药物包括化疗药物、标靶治疗药物、免疫治疗药物和干细胞移植药物。全球血癌盛行率不断上升，以及提高存活率的技术创新需求推动了对这些药物的需求。它适用于多种血癌的治疗方法，有时单独使用或与其他治疗方法结合使用。最终使用领域主要包括医院、诊所和专门的癌症治疗中心，它们越来越多地采用先进的诊断工具来客製化治疗。

主要市场统计
基准年[2023] 427.8亿美元
预测年份 [2024] 459.8亿美元
预测年份 [2030] 828.7亿美元
复合年增长率（%） 9.90%

影响市场的主要成长要素包括药物开发的技术进步、更容易患血癌的老龄化人口的增加以及对恶性的认识和早期发现的提高。个人化医疗的兴起和标靶治疗的发展为透过根据患者的基因谱量身订做治疗方法来改善预后和最大限度地减少副作用提供了绝佳的机会。此外，製药公司和研究机构之间的合作研究加速了药物发现和商业化的进程。

相反，市场成长受到高昂的市场开拓成本、严格的监管要求以及限制患者依从性的现有疗法的副作用的阻碍。药品的取得和负担能力仍然是一个问题，特别是在低收入人口众多的地区。

最有前景的技术创新领域包括基因编辑和次世代定序技术，它们可以更精确地靶向癌细胞，并允许针对个别患者量身定制治疗方法。此外，对癌症免疫疗法和生物资讯学的投资增加将为研究和开发开闢途径。市场格局是动态的，竞争环境的特征是不断的研发努力。因此，市场参与企业必须保持敏捷，专注于策略伙伴关係关係，并优先考虑以患者为中心的创新，以保持竞争力并推动业务成长。

市场动态：揭示快速发展的血癌药物市场的关键市场洞察

供需的动态交互作用正在改变血癌药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 透过扩大医疗基础设施和治疗机会加速血癌药物市场成长
    • 支持血癌药物开发和可近性的政府措施和优惠政策
    • 主要企业之间的策略联盟和伙伴关係，以加速血癌药物开发的进展
    • 老年人口的增加和血癌易感性的增加推动了血癌药物市场的需求
  • 市场限制因素
    • 缺乏认识和早期检测措施影响血癌治疗结果和市场成长
    • 专业治疗设施和医疗保健专业人员数量有限，影响病患照护和市场潜力；
  • 市场机会
    • 血癌治疗市场对个人化医疗解决方案的需求不断增长
    • 生技药品和标靶治疗的进步推动血癌药物的成长
    • 透过提高认识和早期诊断来提高血癌患者的治疗率
  • 市场挑战
    • 主要企业之间的激烈竞争影响血癌药物价格和市场占有率
    • 严格的监管要求和合规障碍影响血癌药物创新

波特五力：驾驭血癌药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对血癌治疗市场的影响

外部宏观环境因素在塑造血癌治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解血癌治疗药物市场的竞争状况

血癌治疗药物市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵血癌治疗市场供应商的绩效评估

FPNV定位矩阵是评估血癌治疗市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，描绘血癌治疗市场的成功之路

血癌药物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告提供了涵盖关键重点领域的市场全面分析：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 扩大医疗基础设施和治疗的覆盖范围，推动血癌药物市场的成长
      • 支持血癌药物开发和可近性的政府措施和优惠政策
      • 主要企业之间的策略合作和伙伴关係加速了血癌药物开发的进展
      • 老年人口的增加和血癌易感性的增加正在推动血癌治疗的市场需求。
    • 抑制因素
      • 缺乏认识和早期检测措施会影响血癌治疗结果和市场成长。
      • 缺乏专门的治疗设施和医疗保健专业人员会影响患者护理和市场潜力。
    • 机会
      • 血癌治疗市场对个人化医疗解决方案的需求不断增长
      • 生物製药和标靶治疗的进步推动血癌药物的成长
      • 提高认识和早期诊断可提高血癌患者的治疗率
    • 任务
      • 主要製药公司之间的激烈竞争影响血癌药物价格和市场占有率
      • 严格的监管要求和合规障碍影响血癌药物创新
  • 市场区隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依药物类型分類的血癌治疗市场

  • 化疗
    • 烷化剂
    • 细胞週期蛋白
    • 抗代谢物
  • 免疫疗法
    • CAR-T细胞疗法
    • 细胞激素
    • 免疫查核点抑制剂
  • 标靶治疗
    • 单株抗体
    • 蛋白酶体抑制剂
    • 蛋白酪氨酸激酶抑制剂

第七章血癌治疗市场：依疾病类型

  • 白血病
    • 急性淋巴性白血病
    • 急性骨髓性白血病
    • 慢性淋巴性白血病
    • 慢性骨髓性白血病
  • 淋巴瘤
    • 何杰金氏淋巴瘤
    • 非何杰金氏淋巴瘤
  • 多发性骨髓瘤
  • 骨髓发育不良症候群

第八章依治疗类型分類的血癌治疗药物市场

  • 强化治疗
  • 诱导治疗
  • 维持治疗
  • 安宁疗护

第九章血癌治疗市场：依最终用户分类

  • 门诊手术中心
  • 诊所
  • 居家护理
  • 医院

第十章 药物处方血癌治疗市场

  • 肌肉注射
  • 静脉
  • 口服
  • 皮下的

第十一章北美和南美的血癌治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区血癌治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章欧洲、中东和非洲的血癌治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064C04E8

The Blood Cancer Drugs Market was valued at USD 42.78 billion in 2023, expected to reach USD 45.98 billion in 2024, and is projected to grow at a CAGR of 9.90%, to USD 82.87 billion by 2030.

The scope of blood cancer drugs centers on pharmaceuticals used in the treatment of different types of blood cancers, including leukemia, lymphoma, and myeloma. These drugs encompass chemotherapeutics, targeted therapies, immunotherapies, and stem cell transplantation drugs. The necessity for these drugs is driven by a growing incidence of blood cancers globally, requiring innovations to improve survival rates. Their application spans across treatment regimens for various blood cancers, sometimes used alone or in combination with other therapies. End-use scope primarily involves hospitals, clinics, and specialized cancer treatment centers, which increasingly employ advanced diagnostic tools to tailor treatments.

KEY MARKET STATISTICS
Base Year [2023] USD 42.78 billion
Estimated Year [2024] USD 45.98 billion
Forecast Year [2030] USD 82.87 billion
CAGR (%) 9.90%

Key growth factors influencing the market include technological advancements in drug development, an expanding aging population susceptible to blood cancers, and increased awareness and early detection of these malignancies. The rise of personalized medicine and the development of targeted therapies offer notable opportunities, as they tailor treatments to a patient's genetic profile, thus improving outcomes and minimizing side effects. Furthermore, collaborations between pharmaceutical companies and research institutions can accelerate drug discovery and commercialization processes.

Conversely, market growth is hindered by high costs associated with drug development, stringent regulatory requirements, and side effects of existing therapies that limit patient compliance. Accessibility and affordability, particularly in lower-income regions, remains a challenge.

The most promising areas of innovation include gene editing and next-generation sequencing technologies, which allow for more precise targeting of cancer cells and tailoring treatment to individual patients. Moreover, increased investment in cancer immunotherapy and bioinformatics presents robust avenues for research and development. The nature of the blood cancer drugs market is dynamic, with a competitive landscape characterized by continuous research and development efforts. This underscores the importance for market players to maintain agility, focus on strategic partnerships, and prioritize patient-centric innovation to remain competitive and drive business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Blood Cancer Drugs Market

The Blood Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Expanding healthcare infrastructure and access to treatment enhancing the blood cancer drugs market growth
    • Government initiatives and favorable policies supporting the development and accessibility of blood cancer drugs
    • Strategic collaborations and partnerships among key players accelerating advancements in blood cancer drug development
    • Increasing geriatric population and their susceptibility to blood cancers driving the market demand for blood cancer therapies
  • Market Restraints
    • Lack of awareness and early detection measures affects blood cancer treatment outcomes and market growth
    • Limited availability of specialized treatment facilities and healthcare professionals impacts patient care and market potential
  • Market Opportunities
    • Increasing demand for personalized medicine solutions in the blood cancer treatment market
    • Advancements in biologics and targeted therapies driving growth in blood cancer medication
    • Growing awareness and early diagnosis leading to higher treatment rates for blood cancer patients
  • Market Challenges
    • High competition among leading pharmaceutical companies affecting blood cancer drug pricing and market share
    • Stringent regulatory requirements and compliance hurdles impacting blood cancer drug innovation

Porter's Five Forces: A Strategic Tool for Navigating the Blood Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Blood Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Blood Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Blood Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Blood Cancer Drugs Market

A detailed market share analysis in the Blood Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Blood Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Blood Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Blood Cancer Drugs Market

A strategic analysis of the Blood Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Blood Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., AstraZeneca PLC, bluebird bio, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Company, Limited, Eisai Co., Ltd., F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline plc, Incyte Corporation, Johnson & Johnson, Karyopharm Therapeutics Inc., Merck & Co., Inc., Novartis International AG, Pfizer Inc., Sanofi S.A., Seattle Genetics, Inc., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Blood Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Chemotherapy, Immunotherapy, and Targeted Therapy. The Chemotherapy is further studied across Alkylating Agents, Anthracyclines, and Antimetabolites. The Immunotherapy is further studied across CAR T-Cell Therapy, Cytokines, and Immune Checkpoint Inhibitors. The Targeted Therapy is further studied across Monoclonal Antibodies, Proteasome Inhibitors, and Tyrosine Kinase Inhibitors.
  • Based on Disease Type, market is studied across Leukemia, Lymphoma, Multiple Myeloma, and Myelodysplastic Syndrome. The Leukemia is further studied across Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, and Chronic Myeloid Leukemia. The Lymphoma is further studied across Hodgkin Lymphoma and Non-Hodgkin Lymphoma.
  • Based on Treatment Type, market is studied across Consolidation Therapy, Induction Therapy, Maintenance Therapy, and Palliative Therapy.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Clinics, Homecare, and Hospitals.
  • Based on Drug Formulation, market is studied across Intramuscular, Intravenous, Oral, and Subcutaneous.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Expanding healthcare infrastructure and access to treatment enhancing the blood cancer drugs market growth
      • 5.1.1.2. Government initiatives and favorable policies supporting the development and accessibility of blood cancer drugs
      • 5.1.1.3. Strategic collaborations and partnerships among key players accelerating advancements in blood cancer drug development
      • 5.1.1.4. Increasing geriatric population and their susceptibility to blood cancers driving the market demand for blood cancer therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of awareness and early detection measures affects blood cancer treatment outcomes and market growth
      • 5.1.2.2. Limited availability of specialized treatment facilities and healthcare professionals impacts patient care and market potential
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing demand for personalized medicine solutions in the blood cancer treatment market
      • 5.1.3.2. Advancements in biologics and targeted therapies driving growth in blood cancer medication
      • 5.1.3.3. Growing awareness and early diagnosis leading to higher treatment rates for blood cancer patients
    • 5.1.4. Challenges
      • 5.1.4.1. High competition among leading pharmaceutical companies affecting blood cancer drug pricing and market share
      • 5.1.4.2. Stringent regulatory requirements and compliance hurdles impacting blood cancer drug innovation
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Blood Cancer Drugs Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Chemotherapy
    • 6.2.1. Alkylating Agents
    • 6.2.2. Anthracyclines
    • 6.2.3. Antimetabolites
  • 6.3. Immunotherapy
    • 6.3.1. CAR T-Cell Therapy
    • 6.3.2. Cytokines
    • 6.3.3. Immune Checkpoint Inhibitors
  • 6.4. Targeted Therapy
    • 6.4.1. Monoclonal Antibodies
    • 6.4.2. Proteasome Inhibitors
    • 6.4.3. Tyrosine Kinase Inhibitors

7. Blood Cancer Drugs Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Leukemia
    • 7.2.1. Acute Lymphocytic Leukemia
    • 7.2.2. Acute Myeloid Leukemia
    • 7.2.3. Chronic Lymphocytic Leukemia
    • 7.2.4. Chronic Myeloid Leukemia
  • 7.3. Lymphoma
    • 7.3.1. Hodgkin Lymphoma
    • 7.3.2. Non-Hodgkin Lymphoma
  • 7.4. Multiple Myeloma
  • 7.5. Myelodysplastic Syndrome

8. Blood Cancer Drugs Market, by Treatment Type

  • 8.1. Introduction
  • 8.2. Consolidation Therapy
  • 8.3. Induction Therapy
  • 8.4. Maintenance Therapy
  • 8.5. Palliative Therapy

9. Blood Cancer Drugs Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Clinics
  • 9.4. Homecare
  • 9.5. Hospitals

10. Blood Cancer Drugs Market, by Drug Formulation

  • 10.1. Introduction
  • 10.2. Intramuscular
  • 10.3. Intravenous
  • 10.4. Oral
  • 10.5. Subcutaneous

11. Americas Blood Cancer Drugs Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Blood Cancer Drugs Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Blood Cancer Drugs Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. AstraZeneca PLC
  • 4. bluebird bio, Inc.
  • 5. Bristol-Myers Squibb Company
  • 6. Celgene Corporation
  • 7. Daiichi Sankyo Company, Limited
  • 8. Eisai Co., Ltd.
  • 9. F. Hoffmann-La Roche Ltd
  • 10. Gilead Sciences, Inc.
  • 11. GlaxoSmithKline plc
  • 12. Incyte Corporation
  • 13. Johnson & Johnson
  • 14. Karyopharm Therapeutics Inc.
  • 15. Merck & Co., Inc.
  • 16. Novartis International AG
  • 17. Pfizer Inc.
  • 18. Sanofi S.A.
  • 19. Seattle Genetics, Inc.
  • 20. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. BLOOD CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. BLOOD CANCER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. BLOOD CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. BLOOD CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BLOOD CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BLOOD CANCER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ANTHRACYCLINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ANTIMETABOLITES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNE CHECKPOINT INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CONSOLIDATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INDUCTION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MAINTENANCE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY PALLIATIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES BLOOD CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 134. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 144. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. INDIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 154. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 160. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 161. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. INDONESIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 164. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 170. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 171. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. JAPAN BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 174. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 177. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 180. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 181. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 183. MALAYSIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 184. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 190. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 194. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 197. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 198. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 200. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 201. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 203. SINGAPORE BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 214. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 217. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 218. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 220. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 221. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 223. TAIWAN BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 224. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 227. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 228. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 230. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 231. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 233. THAILAND BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 234. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 237. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 238. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 240. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 241. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 243. VIETNAM BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 255. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 258. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 259. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 261. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 262. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 264. DENMARK BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 265. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 268. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 269. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 271. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 272. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 273. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 274. EGYPT BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 275. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 278. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 279. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 281. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 282. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 284. FINLAND BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 285. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 288. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 289. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 291. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 292. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 294. FRANCE BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 295. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 297. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 298. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 299. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 301. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 302. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 303. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 304. GERMANY BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 305. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 306. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 307. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 308. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 309. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 310. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 311. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 312. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 313. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 314. ISRAEL BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 315. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 316. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 317. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 318. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 319. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 320. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 321. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 322. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 323. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 324. ITALY BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 325. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 328. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 330. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 332. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 333. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 334. NETHERLANDS BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 335. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 336. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 337. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 338. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 339. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 340. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 341. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2030 (USD MILLION)
  • TABLE 342. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 343. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 344. NIGERIA BLOOD CANCER DRUGS MARKET SIZE, BY DRUG FORMULATION, 2018-2030 (USD MILLION)
  • TABLE 345. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 346. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 347. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, 2018-2030 (USD MILLION)
  • TABLE 348. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, 2018-2030 (USD MILLION)
  • TABLE 349. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 350. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2030 (USD MILLION)
  • TABLE 351. NORWAY BLOOD CANCER DRUGS MARKET SIZE, BY